<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="discussion" dtd-version="3.0" xml:lang="EN">
  <front>
    <journal-meta><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="publisher">pmed</journal-id><journal-id journal-id-type="allenpress-id">plme</journal-id><journal-id journal-id-type="nlm-ta">PLoS Med</journal-id><journal-id journal-id-type="pmc">plosmed</journal-id><!--===== Grouping journal title elements =====--><journal-title-group><journal-title>PLoS Medicine</journal-title></journal-title-group><issn pub-type="ppub">1549-1277</issn><issn pub-type="epub">1549-1676</issn><publisher>
        <publisher-name>Public Library of Science</publisher-name>
        <publisher-loc>San Francisco, USA</publisher-loc>
      </publisher></journal-meta>
    <article-meta><article-id pub-id-type="doi">10.1371/journal.pmed.0040120</article-id><article-id pub-id-type="publisher-id">06-PLME-RIT-0481R2</article-id><article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research in Translation</subject>
        </subj-group>
        <subj-group subj-group-type="Discipline">
          <subject>Infectious Diseases</subject>
          <subject>Infectious Diseases</subject>
          <subject>Infectious Diseases</subject>
          <subject>Infectious Diseases</subject>
          <subject>Microbiology</subject>
          <subject>Microbiology</subject>
          <subject>Microbiology</subject>
          <subject>Microbiology</subject>
          <subject>Pharmacology</subject>
          <subject>Pharmacology</subject>
          <subject>Pharmacology</subject>
          <subject>Public Health and Epidemiology</subject>
        </subj-group>
        <subj-group subj-group-type="System Taxonomy">
          <subject>Tuberculosis</subject>
          <subject>Infectious Diseases</subject>
          <subject>Microbiology</subject>
          <subject>Pharmacology and toxicology</subject>
          <subject>Drugs and adverse drug reactions</subject>
        </subj-group>
      </article-categories><title-group><article-title>Why Is Long-Term Therapy Required to Cure Tuberculosis?</article-title><alt-title alt-title-type="running-head">Research in Translation</alt-title></title-group><contrib-group>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Connolly</surname>
            <given-names>Lynn E</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Edelstein</surname>
            <given-names>Paul H</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author" xlink:type="simple">
          <name name-style="western">
            <surname>Ramakrishnan</surname>
            <given-names>Lalita</given-names>
          </name>
          <xref ref-type="corresp" rid="cor1">
            <sup>*</sup>
          </xref>
        </contrib>
      </contrib-group><author-notes>
        <fn fn-type="con">
          <p> LEC and LR designed the study. LEC, PHE, and LR analyzed the data and wrote the paper. LEC also completed the primary literature review and constructed all tables and figures in the manuscript.</p>
        </fn>
        <fn fn-type="current-aff" id="n3">
          <p>Lynn E. Connolly and Lalita Ramakrishnan are with the Department of Medicine, University of Washington, Seattle, Washington, United States of America. Lalita Ramakrishnan is also with the University of Washington's Departments of Microbiology and Immunology. Paul H. Edelstein is with the Department of Pathology and Laboratory Medicine and the Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America.</p>
        </fn>
        <corresp id="cor1">* To whom correspondence should be addressed. E-mail: <email xlink:type="simple">lalitar@u.washington.edu</email></corresp>
      <fn fn-type="conflict" id="n2">
        <p> LEC is a recipient of a Pfizer Pharmaceuticals Fellowship in Infectious Diseases, 2005–2008. PHE and LR declare that they have no competing interests.</p>
      </fn></author-notes><pub-date pub-type="ppub">
        <month>3</month>
        <year>2007</year>
      </pub-date><pub-date pub-type="epub">
        <day>20</day>
        <month>3</month>
        <year>2007</year>
      </pub-date><volume>4</volume><issue>3</issue><elocation-id>e120</elocation-id><!--===== Grouping copyright info into permissions =====--><permissions><copyright-year>2007</copyright-year><copyright-holder>© 2007 Connolly et al</copyright-holder><license><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract abstract-type="toc">
        <p>The authors argue that understanding and countering general bacterial mechanisms of phenotypic antibiotic resistance may hold the key to reducing the duration of treatment of all recalcitrant bacterial infections, including tuberculosis.</p>
      </abstract><funding-group><funding-statement>This work was supported by the National Institutes of Health grant RO1 AI036396 and a Burroughs Wellcome Pathogenesis of Infectious Diseases Award to LR.</funding-statement></funding-group><counts>
        <page-count count="8"/>
      </counts><!--===== Restructure custom-meta-wrap to custom-meta-group =====--><custom-meta-group>
        <custom-meta>
          <meta-name>citation</meta-name>
          <meta-value>Connolly LE, Edelstein PH, Ramakrishnan L (2007) Why is long-term therapy required to cure tuberculosis? PLoS Med 4(3): e120. doi: <ext-link ext-link-type="doi" xlink:href="http://dx.doi.org/10.1371/journal.pmed.0040120" xlink:type="simple">10.1371/journal.pmed.0040120</ext-link></meta-value>
        </custom-meta>
      </custom-meta-group></article-meta>
  </front>
  <body>
    <sec id="s1">
      <title/>
      <p>A fundamental problem in the treatment of tuberculosis (TB) is the long duration of therapy required for cure. The recalcitrance of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> (MTB) to eradication is thought to result from its achieving a nonreplicating (dormant) state in the host. Because virtually all classes of antibiotics require bacterial replication for their action, the nonreplicating state is thought to render MTB phenotypically resistant to otherwise bactericidal antibiotics.</p>
      <p>Tuberculosis drug discovery efforts have been guided by the belief that MTB achieves this nonreplicating state as the result of specific interactions with the host, particularly residence in certain types of tuberculous granulomas. This belief has placed the imperative on understanding and overcoming TB-specific mechanisms by which the nonreplicating state is achieved. Yet, it is also known that many other pathogenic bacteria display phenotypic drug resistance in vivo, accounting for the need for longer durations of antibiotic therapy than would be predicted from the time required for in vitro bacterial killing. Only recently has attention been given to these general mechanisms to explain the need for prolonged TB therapy.</p>
      <p>In this article, we consider general versus MTB-specific models of phenotypic antibiotic resistance (see Glossary) in light of our review of human TB treatment data. These data suggest that the duration of therapy required for cure correlates with overall bacterial burden. This correlation between bacterial burden and time to cure is not unique to TB, as it has been found in other bacterial infections, both acute and chronic. High bacterial burden infections, in turn, are associated with an increased frequency of phenotypically drug-resistant bacteria. We argue that understanding and countering general bacterial mechanisms of phenotypic antibiotic resistance may hold the key to reducing the duration of treatment of all recalcitrant bacterial infections, including TB.</p>
    </sec>
    <sec id="s2">
      <title>Types and Consequences of MTB Drug Resistance</title>
      <p>Soon after the discovery of streptomycin it became clear that while many patients with TB treated with this drug initially improved dramatically, most developed streptomycin-resistant strains so that there was little improvement in mortality over untreated patients [<xref ref-type="bibr" rid="pmed-0040120-b0001">1</xref>]. The development of new antibiotics led to the realization that there were two requisites for effective cure: treatment with multiple antibiotics and long therapy [<xref ref-type="bibr" rid="pmed-0040120-b0002">2</xref>]. Indeed, the minimum length of treatment and number of drugs required for cure has been more carefully tested for TB than for most infectious diseases (see [<xref ref-type="bibr" rid="pmed-0040120-b0003">3</xref>] and <xref ref-type="supplementary-material" rid="pmed-0040120-st001">Table S1</xref>).</p>
      <boxed-text position="float">
        <sec>
          <title>Glossary</title>
          <p><bold>Antibiotic indifference:</bold> A subtype of phenotypic resistance to antibiotics due to decreased or absent bacterial growth of the entire bacterial population, generally in response to adverse environmental conditions, such as host defense reactions.</p>
          <p><bold>Biofilms:</bold> Multicellular bacterial communities encased in a matrix which demonstrate resistance to antibiotic killing in the absence of genetic resistance mechanisms.</p>
          <p><bold>Dormancy:</bold> A nonreplicating state, thought to be achieved by <named-content content-type="genus-species" xlink:type="simple">M. tuberculosis</named-content> in the host, that renders the bacteria phenotypically resistant to killing by both host immune mechanisms and antibiotics.</p>
          <p><bold>Latency:</bold> Clinically asymptomatic infection with <named-content content-type="genus-species" xlink:type="simple">M. tuberculosis</named-content>.</p>
          <p><bold>Persisters:</bold> A stochastically determined subset of bacteria that arise in an otherwise growing population of bacteria and are in a state of slow or non-growth, rendering them resistant to antibiotics.</p>
          <p><bold>Phenotypic antibiotic resistance:</bold> A general term for the phenomenon by which genetically homogeneous, antibiotic-susceptible bacterial populations (or subpopulations) become transiently insensitive to antibiotic killing.</p>
        </sec>
      </boxed-text>
      <p>The need for multidrug and long-term therapy stems from two different drug resistance mechanisms. MTB can exhibit genetic resistance that is heritable and fixed, as well as phenotypic, reversible resistance to administered antibiotics. The presence of genetic drug resistance in some or all of the infecting bacteria dictates the need for multidrug therapy [<xref ref-type="bibr" rid="pmed-0040120-b0002">2</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0004">4</xref>]. The greater the bacterial burden, the more likely that it contains genetically resistant mutants [<xref ref-type="bibr" rid="pmed-0040120-b0005">5</xref>]. Therapy failure due to genetic resistance is related to the frequency of preexisting resistant mutants and their enrichment by selective pressures imposed by inadequate therapy [<xref ref-type="bibr" rid="pmed-0040120-b0004">4</xref>]. Simultaneous use of multiple anti-TB drugs makes it less likely that a mutant resistant to a single agent will survive.</p>
      <p>MTB also exhibits phenotypic drug resistance. In patients who relapse early after appropriate multidrug therapy, the bacteria remain genetically susceptible to the initial antibiotics and cure is achieved by additional treatment with the same regimen [<xref ref-type="bibr" rid="pmed-0040120-b0006">6</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0007">7</xref>]. This phenomenon may be due to a subpopulation of nonreplicating bacteria that survives until antituberculous therapy is stopped and causes relapse as it resumes growth in the absence of antibiotics. Long-term antibiotic treatment may cure the infection by eradicating these bacterial populations as they periodically leave the nonreplicating state. Further supporting this theory of MTB's development of a nonreplicating and therefore phenotypically resistant state in vivo is the observed discrepancy between in vitro and in vivo antibiotic killing [<xref ref-type="bibr" rid="pmed-0040120-b0008">8</xref>].</p>
      <p>Treatment of MTB with isoniazid (INH), a drug that targets cell wall synthesis, causes a 3-log reduction in broth culture in two hours [<xref ref-type="bibr" rid="pmed-0040120-b0009">9</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0010">10</xref>], whereas more than 14 days of therapy are required to achieve a 3-log reduction in viable bacterial counts in the sputum during active TB [<xref ref-type="bibr" rid="pmed-0040120-b0011">11</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0012">12</xref>] and several months of treatment are required to eradicate latent TB (<xref ref-type="table" rid="pmed-0040120-t001">Table 1</xref>). The role of pyrazinamide in shortening TB therapy to six months may also suggest the existence of a nonreplicating population in vivo, as, unlike other anti-TB drugs, pyrazinamide is more active against nonreplicating than actively replicating MTB in vitro [<xref ref-type="bibr" rid="pmed-0040120-b0013">13</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0014">14</xref>]. Phenotypic antibiotic resistance likely accounts for the need for longer antibiotic therapy in many bacterial infections, presenting a universal obstacle to the treatment of infectious diseases ([<xref ref-type="bibr" rid="pmed-0040120-b0015">15–17</xref>] and <xref ref-type="table" rid="pmed-0040120-t001">Table 1</xref>).</p>
      <table-wrap id="pmed-0040120-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pmed.0040120.t001</object-id><label>Table 1</label><caption>
          <title>Phenotypic Antibiotic Resistance In Vivo Is Common to Many Bacterial Pathogens</title>
        </caption><graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0040120.t001" xlink:type="simple"/><!-- <table frame="hsides" rules="groups"><colgroup><col id="tb1col1" align="left"/><col id="tb1col2" align="left"/><col id="tb1col3" align="left"/><col id="tb1col4" align="left"/><col id="tb1col5" align="left"/><col id="tb1col6" align="left"/><col id="tb1col7" align="left"/></colgroup><thead><tr><td><bold>Organism</bold></td><td><bold>Antibiotic</bold></td><td><bold>3 Log Reduction In Vitro<xref ref-type="fn" rid="nt101"><sup>a</sup></xref></bold></td><td><bold>Disease State</bold></td><td><bold>Duration of Therapy</bold></td><td><bold>&ldquo;Cure Rate&rdquo; In Vivo<xref ref-type="fn" rid="nt102"><sup>b</sup></xref></bold></td><td><bold>References</bold></td></tr></thead><tbody><tr><td>MTB</td><td>INH</td><td>2 hours</td><td>Latent TB</td><td>3 months</td><td>31&percnt;</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0040120-b0009">9</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0010">10</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0081">81</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>6 months</td><td>69&percnt;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>12 months</td><td>93&percnt;</td><td>&nbsp;</td></tr><tr><td><named-content content-type="genus-species">E. coli</named-content></td><td>&szlig;-lactam</td><td>30 minutes</td><td>Cystitis</td><td>1 dose</td><td>66&percnt;</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0040120-b0082">82</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0083">83</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>3 days</td><td>82&percnt;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>8 days</td><td>88&percnt;</td><td>&nbsp;</td></tr><tr><td><named-content content-type="genus-species">Staphylococcus aureus</named-content></td><td>&szlig; -lactam &plus;/&minus; amino-glycoside</td><td>24 hours</td><td>Bacteremia or R-sided endocarditis</td><td>2 weeks</td><td>92&percnt;&ndash;100&percnt;</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0040120-b0084">84&ndash;88</xref>&rsqb;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>L-sided endocarditis</td><td>4&ndash;6 weeks</td><td>50&percnt;&ndash;82&percnt;</td><td>&lsqb;<xref ref-type="bibr" rid="pmed-0040120-b0089">89</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0090">90</xref>&rsqb;</td></tr></tbody></table> --><!-- <table-wrap-foot><fn id="nt101"><p><sup>a</sup>Exponential phase cultures.</p></fn><fn id="nt102"><p><sup>b</sup>Cure rate for latent TB is defined as the percent reduction in cases of active TB in individuals treated with INH versus individuals treated with placebo. Cure rate for <named-content content-type="genus-species">E. coli</named-content> cystitis and <named-content content-type="genus-species">S. aureus</named-content> bacteremia or endocarditis is defined as resolution of clinical symptoms and/or bacteriologic proof of cure.</p></fn></table-wrap-foot> --></table-wrap>
      <p>The impact of phenotypic drug resistance on TB treatment outcomes is particularly dire. In the absence of an effective vaccine, TB eradication is dependent on curing infected individuals who are either contagious or may become contagious after reactivation of latent infection. The relative lack of protective immunity provided by natural infection makes control all the more dependent on complete bacterial eradication from the population, since individuals who are cured of TB remain vulnerable to reinfection [<xref ref-type="bibr" rid="pmed-0040120-b0018">18</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0019">19</xref>]. Drug resistance, and the consequent need for long-term multidrug therapy have stymied TB eradication efforts particularly in poor countries with the highest disease burden. Poor adherence to therapy also has led to an alarming increase in multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains [<xref ref-type="bibr" rid="pmed-0040120-b0020">20</xref>], which are associated with high morbidity and mortality [<xref ref-type="bibr" rid="pmed-0040120-b0021">21</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0022">22</xref>]. Hence the critical need for new drugs to shorten treatment of drug-sensitive TB, and to treat MDR- and XDR-TB.</p>
    </sec>
    <sec id="s3">
      <title>Overview of TB Pathogenesis and Pathology</title>
      <p>A review of TB pathogenesis and pathology will facilitate the assessment of the models proposed for the mechanisms of phenotypic antibiotic resistance of MTB. MTB reaches the alveoli in small, aerosolized particles and is transported into tissues within host macrophages, which aggregate with other immune cells to form granulomas, the hallmark lesion of TB. In immunocompetent individuals, there are two main outcomes of initial infection: the development of active TB or the establishment of a clinically asymptomatic (latent) infection. Active disease is associated with a wide range of granuloma structures [<xref ref-type="bibr" rid="pmed-0040120-b0023">23–25</xref>], including bacteria-laden, necrotic (caseating) lesions undergoing central liquefaction and large open cavities. Patients with active disease also harbor lesions in various stages of healing, including closed granulomas with hard, central caseum, and fibrotic and calcified lesions. These latter types of lesions with lower bacterial burdens [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0026">26</xref>] are the only lesion types detected in latent TB [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>]. However, the actual physical location of viable bacteria during latent infection remains a topic of considerable debate. In latently infected individuals, viable bacteria or bacterial DNA have been detected outside of granulomas in apparently normal tissue [<xref ref-type="bibr" rid="pmed-0040120-b0026">26</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0027">27</xref>]. In contrast, immunocompromised (e.g., HIV-infected) individuals tend to develop disease with poorly organized, noncaseating lesions that contain numerous bacteria [<xref ref-type="bibr" rid="pmed-0040120-b0028">28</xref>].</p>
      <p>In summary, during active disease, numerous bacteria are found in highly organized, caseating, and cavitary lesions of immunocompetent individuals or in poorly organized, noncaseating granulomas of severely immunocompromised individuals, whereas the lesions present in latent TB contain few bacteria and viable bacteria may be present outside of discernible granulomas. The lesions characteristic of latency are also found in immunocompetent individuals with active disease.</p>
    </sec>
    <sec id="s4">
      <title>TB-Specific Model of In Vivo–Induced Phenotypic Antibiotic Resistance</title>
      <p>The first step in understanding MTB phenotypic drug resistance is to address whether it is mediated by TB-specific mechanisms as has been widely postulated, or by mechanisms common to all bacteria. TB-specific models suggest that environmental conditions in specific granuloma types, in particular those associated with latent disease, induce nonreplicating bacterial populations and thereby antimicrobial resistance [<xref ref-type="bibr" rid="pmed-0040120-b0029">29–33</xref>]. This nonreplicating state is thought to be an MTB-specific response to conditions found within closed granulomas such as hypoxia and/or nitric oxide production. According to this model, exposure to these conditions leads to the expression of a discrete set of genes known as the dormancy regulon that are in turn responsible for maintaining the bacilli in the nonreplicating and hence resistant state [<xref ref-type="bibr" rid="pmed-0040120-b0029">29</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0034">34–36</xref>]. The theory that TB-specific, environmentally induced mechanisms lead to sustained phenotypically drug-resistant bacterial populations has led to an emphasis on understanding specific host environments such as hypoxia and the specific bacterial gene expression programs they induce as a basis for developing drugs that intercept this host–bacterial interface [<xref ref-type="bibr" rid="pmed-0040120-b0029">29–33</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0035">35–37</xref>].</p>
      <p>The main argument favoring the environmentally induced in vivo dormancy program specific to MTB is based on observed differences in bacterial growth in vitro depending on the type of human lesion from which the bacteria were isolated [<xref ref-type="bibr" rid="pmed-0040120-b0024">24</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0025">25</xref>]. Cavitary lesions resected from treated patients contained drug-resistant MTB that grew in a normal time frame (eight weeks), whereas “latent”-appearing (closed caseous) lesions from these same patients often contained drug-sensitive bacteria that grew only after three to ten months of incubation. These observations were interpreted to mean that the bacteria from the cavitary lesions were actively replicating and thus susceptible to the administered antibiotics. Therefore, following antibiotic therapy, this niche became populated by the growth of the drug-resistant mutants that were selected for during drug treatment.</p>
      <p>In contrast, the bacteria in the closed lesions were thought to have been driven into a nonreplicating state by adverse conditions present within the lesion prior to antibiotic therapy. The nonreplicating state of the bacteria in these lesions was felt to account for both characteristics observed in vitro: the slower growth due to the need to overcome this dormant state as well as drug sensitivity owing to their never having been acted upon by the antibiotic in vivo. These differences were felt to be unlikely to be due to a lack of drug exposure in the closed lesions, because several of the agents used have been shown to penetrate both types of lesions [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0038">38</xref>]. However, these findings could have had an alternate explanation, which was not considered. The slower growing, drug-sensitive bacteria could have been present in the open lesions but their in vitro detection masked by the more rapidly growing, drug-resistant bacteria. If true, this would mean that the nonreplicating state is not specifically induced by the environment present in the closed lesions but is present in all bacterial populations and lesion types in vivo.</p>
    </sec>
    <sec id="s5">
      <title>Do Human Pulmonary TB Treatment Trials Inform Us about Mechanisms of Phenotypic Antibiotic Resistance?</title>
      <p>Another problem with the TB-specific model is that it implicates the lesions that are associated with few bacteria in inducing bacterial phenotypic antibiotic resistance. However, short-course treatment trials for pulmonary TB suggest that the duration of treatment required to prevent relapse of active disease is directly proportional to the organism burden, rather than the predominant type of granuloma microenvironment present (<xref ref-type="fig" rid="pmed-0040120-g001">Figures 1</xref> and <xref ref-type="fig" rid="pmed-0040120-g002">2</xref>, <xref ref-type="supplementary-material" rid="pmed-0040120-st001">Table S1</xref>). Smear-positive and cavitary disease states are associated with the highest organism burden [<xref ref-type="bibr" rid="pmed-0040120-b0012">12</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0039">39</xref>] and require the longest duration of therapy to effect cure (<xref ref-type="fig" rid="pmed-0040120-g001">Figures 1</xref> and <xref ref-type="fig" rid="pmed-0040120-g002">2</xref>). In contrast, both HIV-positive and HIV-negative individuals with latent TB, which is characterized by low bacterial burden, are readily “cured” with single-drug therapy (<xref ref-type="supplementary-material" rid="pmed-0040120-st001">Table S1</xref>). Twelve months of INH therapy in adherent populations with a low risk of reinfection leads to a 92%–93% reduction in the rate of active disease [<xref ref-type="bibr" rid="pmed-0040120-b0040">40</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0041">41</xref>]. This reduction, using a single drug, is comparable to that seen in treating high-burden, active disease with multidrug therapy, underscoring the importance of bacterial burden as one of the main determinants of successful treatment. The high relapse rate of cavitary disease may also be related to poor penetration of the cavity by antibiotics, due to the dense, fibrous capsule surrounding these lesions [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>]. However, some studies have shown that antibiotics do penetrate such lesions [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0038">38</xref>]. This point is underscored by the growth of resistant bacteria from these lesions in the studies described in the previous section [<xref ref-type="bibr" rid="pmed-0040120-b0024">24</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0025">25</xref>].</p>
      <fig id="pmed-0040120-g001" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pmed.0040120.g001</object-id>
        <label>Figure 1</label>
        <caption>
          <title>Duration of Curative Therapy for Pulmonary Tuberculosis Correlates Directly with Organism Burden</title>
          <p>Pulmonary TB with a low bacterial burden (smear negative, culture negative [Cx-]; white bars) requires the shortest duration of four-drug therapy to achieve relapse rates &lt;10%. Moderate burden (smear negative, culture positive [Cx+]; grey bars) patients require intermediate treatment courses, while high burden (smear positive, Cx+; black bars) cases require the longest duration of therapy. All patients were HIV negative and were treated with six months of therapy consisting of streptomycin (S), isoniazid (H), rifampin (R), and pyrazinamide (Z) during the intensive phase, followed by SHRZ or HR combinations in the continuation phase. Data for the figure were obtained from references [<xref ref-type="bibr" rid="pmed-0040120-b0078">78–80</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0091">91–95</xref>].</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0040120.g001" xlink:type="simple"/>
      </fig>
      <fig id="pmed-0040120-g002" position="float">
        <object-id pub-id-type="doi">10.1371/journal.pmed.0040120.g002</object-id>
        <label>Figure 2</label>
        <caption>
          <title>Duration of Curative Therapy Is Longest for Disease States Associated with High-Organism Burden Lesions</title>
          <p>(A) Active TB associated with cavitary lesions requires longest duration of therapy to cure. Treated pulmonary TB with open lesions and the highest bacterial burden (cavitary lesions with positive sputum cultures [Cx+] after two months of therapy; black bars) is associated with higher rates of relapse than are disease states associated with closed lesions (noncavitary, culture negative [Cx-] at two months; white bars, and noncavitary, Cx+ at two months; dark gray bars) or with lower bacterial burdens (noncavitary, Cx- at two months; white bars, or cavitary, Cx- at two months; light gray bars). All patients were HIV negative and received isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) or streptomycin (S) during the intensive phase followed by HR or H plus rifapentine (P) in the continuation phase.</p>
          <p>(B) Active disease states characterized by well-organized (HIV-) or poorly organized (HIV+) lesions require the same duration of therapy for cure. The relapse rate for high-burden (smear-positive) disease states associated with well-organized, cavitary lesions (HIV-; black bars) or loosely organized, noncaseating lesions (HIV+; white bars) treated with standard therapy (EHRZ for two months followed by HR for four months) is the same. Data for HIV+ and HIV- individuals were obtained from references [<xref ref-type="bibr" rid="pmed-0040120-b0096">96</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0097">97</xref>].</p>
        </caption>
        <graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pmed.0040120.g002" xlink:type="simple"/>
      </fig>
      <p>An alternative explanation for the long duration of therapy required to treat active disease states associated with the highest bacterial burden (e.g., smear positive and cavitary disease) is that those individuals with active disease have a greater burden of bacteria present in “latent-type” lesions than do those with low burden or latent disease. According to this interpretation, it is the total burden of bacteria present within these “latent” lesions that dictates the duration of therapy rather than the overall burden. However, this interpretation fails to explain the finding that HIV-infected individuals who tend to have poorly formed, noncaseating granulomas with high bacillary burdens [<xref ref-type="bibr" rid="pmed-0040120-b0028">28</xref>] also require long durations of therapy (<xref ref-type="fig" rid="pmed-0040120-g002">Figure 2</xref> and <xref ref-type="supplementary-material" rid="pmed-0040120-st001">Table S1</xref>) [<xref ref-type="bibr" rid="pmed-0040120-b0028">28</xref>]. Further, the lesion-specific model does not account for the findings that MTB exhibits nonreplicating states [<xref ref-type="bibr" rid="pmed-0040120-b0042">42</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0043">43</xref>] and phenotypic drug resistance [<xref ref-type="bibr" rid="pmed-0040120-b0044">44</xref>] during experimental infection of the mouse, an animal that forms poorly organized macrophage and lymphocyte aggregates that do not resemble human, caseating lesions. Together, these observations are most consistent with the conclusion that phenotypically drug-resistant MTB is present in all lesions rather than being restricted to “latent” granuloma environments.</p>
    </sec>
    <sec id="s6">
      <title>Non-TB Specific Models to Explain the Problem of Phenotypic Drug Resistance</title>
      <p>The human treatment trial data are most readily explained by a model in which infections characterized by the highest organism burden (be it in cavitary lesions, caseating lesions undergoing liquefaction, or poorly formed noncaseating granulomas typical of advanced HIV coinfection) also have the highest number of phenotypically drug-resistant bacteria. Because high organism burden is associated with phenotypic resistance in other infectious diseases, we propose that the mechanisms are similar in MTB and other pathogenic bacteria. We will describe the possible mechanisms briefly here; for more detailed reviews of specific mechanisms see references [<xref ref-type="bibr" rid="pmed-0040120-b0015">15–17</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0045">45</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0046">46</xref>].</p>
      <p>Killing rates of actively growing MTB cultures are dramatically greater than killing rates of stationary-phase MTB cultures, in which the bacteria are resistant to killing in the absence of genetic resistance mechanisms [<xref ref-type="bibr" rid="pmed-0040120-b0009">9</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0010">10</xref>]. This phenomenon had previously been described in other bacterial systems and the term antibiotic indifference was coined to describe the finding that bacteria that are not dividing, due to some inhibitory environmental condition, are resistant to killing by most antibiotics [<xref ref-type="bibr" rid="pmed-0040120-b0047">47</xref>]. This phenomenon is not limited to in vitro culture systems. For example, the dose of penicillin required to cure experimental infections in animals is proportional to the total bacterial burden (both inoculum size and duration of infection). As the infection progresses, bacterial growth slows and eventually stops due to a variety of inhibitory conditions encountered in the host, rendering the residual population phenotypically antibiotic resistant [<xref ref-type="bibr" rid="pmed-0040120-b0047">47–49</xref>]. One potential mechanism for MTB dormancy and phenotypic antibiotic tolerance in vivo is the development of antibiotic indifference in response to host defense mechanisms or nutrient deprivation. Although nutrient deprivation has long been proposed as one of the signals leading to mycobacterial dormancy, this mechanism need not be restricted to specific granuloma pathologies and is clearly not unique to MTB.</p>
      <p>In addition to drug indifference, non-inherited drug resistance can also be explained by the observation that populations of actively growing bacteria contain a specialized, nonreplicating subpopulation known as persister cells [<xref ref-type="bibr" rid="pmed-0040120-b0050">50</xref>]. Like drug-indifferent bacteria, these persister cells remain genetically drug sensitive but are phenotypically drug resistant, and their number increases with total organism burden [<xref ref-type="bibr" rid="pmed-0040120-b0051">51</xref>]. Although the initial establishment of the persister population is likely to be stochastic [<xref ref-type="bibr" rid="pmed-0040120-b0052">52</xref>], the magnitude of this population may be further influenced by specific conditions operant in vivo such as growth in macrophages [<xref ref-type="bibr" rid="pmed-0040120-b0053">53</xref>] or biofilms [<xref ref-type="bibr" rid="pmed-0040120-b0054">54</xref>]. For example, <named-content content-type="genus-species" xlink:type="simple">Legionella pneumophila</named-content> grown in macrophages is more antibiotic resistant than broth-grown bacteria, suggesting that intramacrophage growth enriches phenotypically antibiotic-resistant populations [<xref ref-type="bibr" rid="pmed-0040120-b0053">53</xref>]. This might occur because host-killing mechanisms may also target actively replicating bacteria [<xref ref-type="bibr" rid="pmed-0040120-b0046">46</xref>]. Further, bacteria that have incurred DNA damage, perhaps as a result of host-killing mechanisms, undergo replication arrest to allow for DNA repair, rendering them transiently insensitive to antibiotic killing [<xref ref-type="bibr" rid="pmed-0040120-b0055">55</xref>]. Some antibiotics actually induce DNA repair systems [<xref ref-type="bibr" rid="pmed-0040120-b0056">56</xref>], halting bacterial division and theoretically rendering these bacteria even more resistant to therapy.</p>
      <p>The molecular mechanisms of persister formation are beginning to be elucidated and include growth arrest secondary to the action of toxin–antitoxin modules [<xref ref-type="bibr" rid="pmed-0040120-b0057">57</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0058">58</xref>]. The toxin portion of these modules acts to cleave mRNAs positioned in the ribosome, leading to translational and growth arrest [<xref ref-type="bibr" rid="pmed-0040120-b0059">59</xref>]. Numerous putative toxin–antitoxin modules are found in the MTB genome [<xref ref-type="bibr" rid="pmed-0040120-b0060">60</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0061">61</xref>] and some of these have been shown to cause translational arrest when expressed in <named-content content-type="genus-species" xlink:type="simple">Escherichia coli</named-content> [<xref ref-type="bibr" rid="pmed-0040120-b0062">62</xref>], but their role(s) in persister formation, in vivo survival, and/or drug indifference are unknown. <italic>relA</italic>, a gene involved in the bacterial response to starvation, has also been shown to play a role in some types of persister formation in <named-content content-type="genus-species" xlink:type="simple">E. coli</named-content> [<xref ref-type="bibr" rid="pmed-0040120-b0063">63</xref>]. Although a potential role for <italic>relA</italic> in mycobacterial phenotypic drug resistance has not been shown, <italic>relA</italic> is required for chronic infection in the mouse model of TB [<xref ref-type="bibr" rid="pmed-0040120-b0064">64</xref>], suggesting a possible connection to mechanisms of resistance to both host- and antibiotic-mediated killing.</p>
      <p>Studies of other chronic bacterial infections suggest that biofilm formation is responsible for the relative in vivo resistance to antibiotic killing [<xref ref-type="bibr" rid="pmed-0040120-b0065">65</xref>]. Biofilms are multicellular bacterial communities encased in a matrix and bacteria within biofilms are phenotypically resistant to antibiotic killing when compared to growing planktonic cells [<xref ref-type="bibr" rid="pmed-0040120-b0066">66</xref>]. Examples of important biofilm infections in humans include <named-content content-type="genus-species" xlink:type="simple">Pseudomonas aeruginosa</named-content> lung infections in cystic fibrosis, endocarditis, and device-related infections. Key aspects of MTB biology are reminiscent of biofilm behavior. For example, MTB in liquid culture grows as large clumps of cells known as cords. The ability to cord in culture correlates with virulence [<xref ref-type="bibr" rid="pmed-0040120-b0067">67–69</xref>], suggesting that the capacity to grow in a multicellular community is an important determinant of MTB survival in the host. MTB may also be found in a biofilm-like state in vivo. For example, large clumps of bacteria reside in an acellular matrix in certain human lesions, such as caseating lesions undergoing liquefaction [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>]. Biofilms of other mycobacterial species have been shown to be phenotypically antibiotic resistant [<xref ref-type="bibr" rid="pmed-0040120-b0070">70</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0071">71</xref>] and <named-content content-type="genus-species" xlink:type="simple">M. avium</named-content> biofilm-associated genes are required for mouse infection [<xref ref-type="bibr" rid="pmed-0040120-b0072">72</xref>], further supporting the notion that biofilms may play key roles in mycobacterial drug resistance and virulence.</p>
      <boxed-text position="float">
        <sec>
          <title>Five Key Papers in the Field</title>
          <list list-type="order">
            <list-item>
              <p><bold>Canetti G, 1955</bold> [<xref ref-type="bibr" rid="pmed-0040120-b0023">23</xref>] A seminal text describing the pathology of human pulmonary tuberculosis with particular focus on the bacillary content of different types of lesions.</p>
            </list-item>
            <list-item>
              <p><bold>Vandiviere HM et al., 1956</bold> [<xref ref-type="bibr" rid="pmed-0040120-b0025">25</xref>] A detailed description of growth rates and antibiotic resistance patterns of <named-content content-type="genus-species" xlink:type="simple">M. tuberculosis</named-content> isolated from different types of human tuberculous lesions, which has strongly influenced thinking in the field regarding mechanisms of bacterial phenotypic antibiotic resistance in vivo.</p>
            </list-item>
            <list-item>
              <p><bold>Balaban NQ et al., 2004</bold> [<xref ref-type="bibr" rid="pmed-0040120-b0052">52</xref>] Provides the first direct evidence that persisters are a preexisting population of non-dividing cells within a growing culture using ground-breaking techniques to study persisters at the single cell level.</p>
            </list-item>
            <list-item>
              <p><bold>Keren I et al., 2004</bold> [<xref ref-type="bibr" rid="pmed-0040120-b0057">57</xref>] First paper to describe global gene expression profiles in an isolated population of antibiotic-treated persister cells, supporting the role of toxin–antitoxin modules in persister biology. Later studies of naïve persisters have confirmed these results.</p>
            </list-item>
            <list-item>
              <p><bold>Hong Kong Chest Service/ Tuberculosis Research Centre, Madras/British Medical Research Council, 1984, 1987, and 1989</bold> [<xref ref-type="bibr" rid="pmed-0040120-b0078">78–80</xref>] A series of controlled trials of varying treatment durations for both smear-negative and -positive pulmonary tuberculosis that confirm bacillary burden to be one of the main determinants of duration of therapy required for cure.</p>
            </list-item>
          </list>
        </sec>
      </boxed-text>
      <p>The phenotypic resistance to antibiotics exhibited by bacteria within biofilms is likely multifactorial. Proposed mechanisms of resistance include poor antibiotic penetration of the biofilm, expression of biofilm genes that confer resistance, and the presence of different microenvironments in the biofilm that lead to different growth rates and thus differing antibiotic sensitivity [<xref ref-type="bibr" rid="pmed-0040120-b0045">45</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0065">65</xref>]. One prominent school of thought is that the biofilm environment may also enrich the formation of persister cells [<xref ref-type="bibr" rid="pmed-0040120-b0054">54</xref>,<xref ref-type="bibr" rid="pmed-0040120-b0073">73</xref>]</p>
    </sec>
    <sec id="s7">
      <title>Summary and Proposed Areas of Research</title>
      <p>New drugs that target nonreplicating bacteria are likely to revolutionize TB therapy. Such agents have the potential not only to treat MDR and XDR strains but also to dramatically shorten the duration of curative therapy. Shorter treatment times will likely translate into higher patient adherence, reduced transmission, and decreased drug resistance, leading in turn to diminished mortality and substantial gains in tuberculosis control efforts. For example, mathematical models based on the current situation in Southeast Asia estimate that a two month regimen could prevent ~25% of deaths and ~20% of new cases over a 18-year period compared to current treatment regimens [<xref ref-type="bibr" rid="pmed-0040120-b0074">74</xref>].</p>
      <p>A major obstacle for such truly short-course therapy is the development of phenotypic antibiotic resistance in vivo. This phenomenon is common to all bacteria and these resistant populations may be enriched under a variety of conditions that are operant in vivo, such as intracellular growth, DNA damage, exposure to other antimicrobials, and biofilm formation. In addition to studying possible TB-specific mechanisms of phenotypic drug resistance, we suggest that the study of mycobacterial persister formation and biofilm-like growth states may lead to drug discovery. Additionally, a better understanding of mechanisms of phenotypic antibiotic resistance in other pathogenic bacteria will likely have implications for MTB therapy. Given our current understanding, the development of antibiotics that are effective against non-dividing bacteria is of potential great importance [<xref ref-type="bibr" rid="pmed-0040120-b0075">75</xref>]. Promising candidates under investigation include the ATP synthase inhibitor R207910 [<xref ref-type="bibr" rid="pmed-0040120-b0076">76</xref>]; however, MTB mutants resistant to this agent have been found even before clinical trials have been completed [<xref ref-type="bibr" rid="pmed-0040120-b0077">77</xref>]. Development of additional drugs that target bacterial or host programs that induce phenotypic antibiotic resistance mechanisms will be aided by a better understanding of the physiology of this MTB population and the conditions that induce or enrich it.</p>
    </sec>
    <sec id="s8">
      <title>Supporting Information</title>
      <supplementary-material id="pmed-0040120-st001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pmed.0040120.st001" xlink:type="simple">
        <label>Table S1</label>
        <caption>
          <title>Summary of treatment trials demonstrating direct relationship between minimal duration of curative therapy and bacterial burden</title>
          <p>(115 KB DOC).</p>
        </caption>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack>
      <p>This manuscript was based on material presented by LR at the Bill and Melinda Gates Foundation workshop on the Biology of Persistence in Tres Cantos, Spain, May 17–18, 2005. LR thanks Ira Tager for first stimulating her interest in this area during her infectious diseases fellowship. We thank Christine Cosma, Peter Small, E. Peter Greenberg, Erik Boettger, and David Sherman for stimulating discussions, and Christine Cosma and Mark Miller for critical review of the manuscript. LEC was supported by a Pfizer Pharmaceuticals Postdoctoral Fellowship in Infectious Diseases.</p>
    </ack>
    
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>INH</term>
          <def>
            <p>isoniazid</p>
          </def>
        </def-item>
        <def-item>
          <term>MDR-TB</term>
          <def>
            <p>multidrug-resistant tuberculosis</p>
          </def>
        </def-item>
        <def-item>
          <term>MTB</term>
          <def>
            <p>
              <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>
            </p>
          </def>
        </def-item>
        <def-item>
          <term>TB</term>
          <def>
            <p>tuberculosis</p>
          </def>
        </def-item>
        <def-item>
          <term>XDR-TB</term>
          <def>
            <p>extensively drug-resistant tuberculosis</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <ref-list>
      <title>References</title>
      <ref id="pmed-0040120-b0001">
        <label>1</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">Medical Research Council</collab>
					<year>1948</year>
					<article-title>Streptomycin treatment of pulmonary tuberculosis.</article-title>
					<source>BMJ</source>
					<volume>2</volume>
					<fpage>769</fpage>
					<lpage>782</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0002">
        <label>2</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>2005</year>
					<article-title>The diagnosis and therapy of tuberculosis during the past 100 years.</article-title>
					<source>Am J Respir Crit Care Med</source>
					<volume>171</volume>
					<fpage>699</fpage>
					<lpage>706</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0003">
        <label>3</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Fox</surname><given-names>W</given-names></name><name name-style="western"><surname>Ellard</surname><given-names>GA</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>1999</year>
					<article-title>Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946–1986, with relevant subsequent publications.</article-title>
					<source>Int J Tuberc Lung Dis</source>
					<volume>3</volume>
					<fpage>S231</fpage>
					<lpage>S279</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0004">
        <label>4</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name><name name-style="western"><surname>Nunn</surname><given-names>AJ</given-names></name></person-group>
					<year>1986</year>
					<article-title>Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>133</volume>
					<fpage>423</fpage>
					<lpage>430</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0005">
        <label>5</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>David</surname><given-names>H</given-names></name></person-group>
					<year>1970</year>
					<article-title>Probability distribution of drug-resistant mutants in unselected populations of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Appl Microbiol</source>
					<volume>20</volume>
					<fpage>810</fpage>
					<lpage>814</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0006">
        <label>6</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">Centers for Disease Control and Prevention</collab>
					<year>2003</year>
					<article-title>Treatment of tuberculosis.</article-title>
					<source>MMWR Recomm Rep</source>
					<volume>52</volume>
					<fpage>1</fpage>
					<lpage>77</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0007">
        <label>7</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Wallis</surname><given-names>RS</given-names></name><name name-style="western"><surname>Patil</surname><given-names>S</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>SH</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>K</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>M</given-names></name><etal/></person-group>
					<year>1999</year>
					<article-title>Drug tolerance in <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>43</volume>
					<fpage>2600</fpage>
					<lpage>2606</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0008">
        <label>8</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>1979</year>
					<article-title>Basic mechanisms of chemotherapy.</article-title>
					<source>Chest</source>
					<volume>76</volume>
					<fpage>771</fpage>
					<lpage>781</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0009">
        <label>9</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Paramasivan</surname><given-names>CN</given-names></name><name name-style="western"><surname>Sulochana</surname><given-names>S</given-names></name><name name-style="western"><surname>Kubendiran</surname><given-names>G</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>P</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>2005</year>
					<article-title>Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>49</volume>
					<fpage>627</fpage>
					<lpage>631</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0010">
        <label>10</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Herbert</surname><given-names>D</given-names></name><name name-style="western"><surname>Paramasivan</surname><given-names>CN</given-names></name><name name-style="western"><surname>Venkatesan</surname><given-names>P</given-names></name><name name-style="western"><surname>Kubendiran</surname><given-names>G</given-names></name><name name-style="western"><surname>Prabhakar</surname><given-names>R</given-names></name><etal/></person-group>
					<year>1996</year>
					<article-title>Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>40</volume>
					<fpage>2296</fpage>
					<lpage>2299</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0011">
        <label>11</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Jindani</surname><given-names>A</given-names></name><name name-style="western"><surname>Aber</surname><given-names>VR</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>EA</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>1980</year>
					<article-title>The early bactericidal activity of drugs in patients with pulmonary tuberculosis.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>121</volume>
					<fpage>939</fpage>
					<lpage>949</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0012">
        <label>12</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Hobby</surname><given-names>GL</given-names></name><name name-style="western"><surname>Holman</surname><given-names>AP</given-names></name><name name-style="western"><surname>Iseman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Jones</surname><given-names>JM</given-names></name></person-group>
					<year>1973</year>
					<article-title>Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>4</volume>
					<fpage>94</fpage>
					<lpage>104</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0013">
        <label>13</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Heifets</surname><given-names>L</given-names></name><name name-style="western"><surname>Lindholm-Levy</surname><given-names>P</given-names></name></person-group>
					<year>1992</year>
					<article-title>Pyrazinamide sterilizing activity in vitro against semidormant <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> bacterial populations.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>145</volume>
					<fpage>1223</fpage>
					<lpage>1225</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0014">
        <label>14</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coates</surname><given-names>AR</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>2006</year>
					<article-title>Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Int J Tuberc Lung Dis</source>
					<volume>10</volume>
					<fpage>317</fpage>
					<lpage>322</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0015">
        <label>15</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Levin</surname><given-names>BR</given-names></name><name name-style="western"><surname>Rozen</surname><given-names>DE</given-names></name></person-group>
					<year>2006</year>
					<article-title>Non-inherited antibiotic resistance.</article-title>
					<source>Nat Rev Microbiol</source>
					<volume>4</volume>
					<fpage>556</fpage>
					<lpage>562</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0016">
        <label>16</label>
        <element-citation publication-type="other" xlink:type="simple">
					<person-group><name name-style="western"><surname>Dhar</surname><given-names>N</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>JD</given-names></name></person-group>
					<year>2007</year>
					<article-title>Microbial phenotypic heterogeneity and antibiotic tolerance.</article-title>
					<source>Curr Opin Microbiol</source>
					<comment>E-pub 8 January 2006</comment>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0017">
        <label>17</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Lewis</surname><given-names>K</given-names></name></person-group>
					<year>2007</year>
					<article-title>Persister cells, dormancy and infectious disease.</article-title>
					<source>Nat Rev Microbiol</source>
					<volume>5</volume>
					<fpage>48</fpage>
					<lpage>56</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0018">
        <label>18</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Chiang</surname><given-names>CY</given-names></name><name name-style="western"><surname>Riley</surname><given-names>LW</given-names></name></person-group>
					<year>2005</year>
					<article-title>Exogenous reinfection in tuberculosis.</article-title>
					<source>Lancet Infect Dis</source>
					<volume>5</volume>
					<fpage>629</fpage>
					<lpage>636</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0019">
        <label>19</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Verver</surname><given-names>S</given-names></name><name name-style="western"><surname>Warren</surname><given-names>RM</given-names></name><name name-style="western"><surname>Beyers</surname><given-names>N</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>M</given-names></name><name name-style="western"><surname>van der Spuy</surname><given-names>GD</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.</article-title>
					<source>Am J Respir Crit Care Med</source>
					<volume>171</volume>
					<fpage>1430</fpage>
					<lpage>1435</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0020">
        <label>20</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">Centers for Disease Control and Prevention</collab>
					<year>2006</year>
					<article-title>Emergence of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> with extensive resistance to second-line drugs—worldwide, 2000–2004.</article-title>
					<source>MMWR Morb Mortal Wkly Rep</source>
					<volume>55</volume>
					<fpage>301</fpage>
					<lpage>305</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0021">
        <label>21</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Gandhi</surname><given-names>NR</given-names></name><name name-style="western"><surname>Moll</surname><given-names>A</given-names></name><name name-style="western"><surname>Pawinski</surname><given-names>R</given-names></name><name name-style="western"><surname>Sturm</surname><given-names>AW</given-names></name><name name-style="western"><surname>Lalloo</surname><given-names>U</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Extensively drug-resistant (XDR) tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa.</article-title>
					<source>Lancet</source>
					<volume>368</volume>
					<fpage>1575</fpage>
					<lpage>1580</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0022">
        <label>22</label>
        <element-citation publication-type="other" xlink:type="simple">
					<person-group><name name-style="western"><surname>Cox</surname><given-names>H</given-names></name><name name-style="western"><surname>Kebede</surname><given-names>Y</given-names></name><name name-style="western"><surname>Allamuratova</surname><given-names>S</given-names></name><name name-style="western"><surname>Ismailov</surname><given-names>G</given-names></name><name name-style="western"><surname>Davletmuratova</surname><given-names>Z</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Tuberculosis recurrence and mortality after successful treatment: Impact of drug resistance.</article-title>
					<comment>PLoS Med 3: e384. doi:10.1371/journal.pmed.0030384</comment>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0023">
        <label>23</label>
        <element-citation publication-type="other" xlink:type="simple">
					<person-group><name name-style="western"><surname>Canetti</surname><given-names>G</given-names></name></person-group>
					<year>1955</year>
					<source>The tubercle bacillus in the pulmonary lesion of man: Histobacteriology and its bearing on the therapy of pulmonary tuberculosis</source>
					<publisher-loc>New York</publisher-loc>
					<publisher-name>Springer Publishing Company</publisher-name>
					<fpage>226</fpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0024">
        <label>24</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Kaplan</surname><given-names>G</given-names></name><name name-style="western"><surname>Post</surname><given-names>FA</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>AL</given-names></name><name name-style="western"><surname>Wainwright</surname><given-names>H</given-names></name><name name-style="western"><surname>Kreiswirth</surname><given-names>BN</given-names></name><etal/></person-group>
					<year>2003</year>
					<article-title><named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> growth at the cavity surface: A microenvironment with failed immunity.</article-title>
					<source>Infect Immun</source>
					<volume>71</volume>
					<fpage>7099</fpage>
					<lpage>7108</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0025">
        <label>25</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Vandiviere</surname><given-names>HM</given-names></name><name name-style="western"><surname>Loring</surname><given-names>WE</given-names></name><name name-style="western"><surname>Melvin</surname><given-names>I</given-names></name><name name-style="western"><surname>Willis</surname><given-names>S</given-names></name></person-group>
					<year>1956</year>
					<article-title>The treated pulmonary lesion and its tubercle bacillus. II. The death and resurrection.</article-title>
					<source>Am J Med Sci</source>
					<volume>232</volume>
					<fpage>30</fpage>
					<lpage>37</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0026">
        <label>26</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Opie</surname><given-names>EL</given-names></name><name name-style="western"><surname>Aronson</surname><given-names>JD</given-names></name></person-group>
					<year>1927</year>
					<article-title>Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculosis lesions.</article-title>
					<source>Arch Pathol Lab Med</source>
					<volume>4</volume>
					<fpage>1</fpage>
					<lpage>21</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0027">
        <label>27</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Hernandez-Pando</surname><given-names>R</given-names></name><name name-style="western"><surname>Jeyanathan</surname><given-names>M</given-names></name><name name-style="western"><surname>Mengistu</surname><given-names>G</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>D</given-names></name><name name-style="western"><surname>Orozco</surname><given-names>H</given-names></name><etal/></person-group>
					<year>2000</year>
					<article-title>Persistence of DNA from <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> in superficially normal lung tissue during latent infection.</article-title>
					<source>Lancet</source>
					<volume>356</volume>
					<fpage>2133</fpage>
					<lpage>2138</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0028">
        <label>28</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Di Perri</surname><given-names>G</given-names></name><name name-style="western"><surname>Cazzadori</surname><given-names>A</given-names></name><name name-style="western"><surname>Vento</surname><given-names>S</given-names></name><name name-style="western"><surname>Bonora</surname><given-names>S</given-names></name><name name-style="western"><surname>Malena</surname><given-names>M</given-names></name><etal/></person-group>
					<year>1996</year>
					<article-title>Comparative histopathological study of pulmonary tuberculosis in human immunodeficiency virus-infected and non-infected patients.</article-title>
					<source>Tuber Lung Dis</source>
					<volume>77</volume>
					<fpage>244</fpage>
					<lpage>249</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0029">
        <label>29</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Boshoff</surname><given-names>HI</given-names></name><name name-style="western"><surname>Barry</surname><given-names>CE</given-names><suffix>3rd</suffix></name></person-group>
					<year>2005</year>
					<article-title>Tuberculosis—Metabolism and respiration in the absence of growth.</article-title>
					<source>Nat Rev Microbiol</source>
					<volume>3</volume>
					<fpage>70</fpage>
					<lpage>80</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0030">
        <label>30</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name></person-group>
					<year>2001</year>
					<article-title>Tuberculosis: Latency and reactivation.</article-title>
					<source>Infect Immun</source>
					<volume>69</volume>
					<fpage>4195</fpage>
					<lpage>4201</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0031">
        <label>31</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Gomez</surname><given-names>JE</given-names></name><name name-style="western"><surname>McKinney</surname><given-names>JD</given-names></name></person-group>
					<year>2004</year>
					<article-title><named-content content-type="genus-species" xlink:type="simple">M. tuberculosis</named-content> persistence, latency, and drug tolerance.</article-title>
					<source>Tuberculosis (Edinb)</source>
					<volume>84</volume>
					<fpage>29</fpage>
					<lpage>44</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0032">
        <label>32</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Hingley-Wilson</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sambandamurthy</surname><given-names>VK</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name></person-group>
					<year>2003</year>
					<article-title>Survival perspectives from the world's most successful pathogen, <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Nat Immunol</source>
					<volume>4</volume>
					<fpage>949</fpage>
					<lpage>955</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0033">
        <label>33</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Parrish</surname><given-names>NM</given-names></name><name name-style="western"><surname>Dick</surname><given-names>JD</given-names></name><name name-style="western"><surname>Bishai</surname><given-names>WR</given-names></name></person-group>
					<year>1998</year>
					<article-title>Mechanisms of latency in <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Trends Microbiol</source>
					<volume>6</volume>
					<fpage>107</fpage>
					<lpage>112</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0034">
        <label>34</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Boon</surname><given-names>C</given-names></name><name name-style="western"><surname>Dick</surname><given-names>T</given-names></name></person-group>
					<year>2002</year>
					<article-title><named-content content-type="genus-species" xlink:type="simple">Mycobacterium bovis</named-content> BCG response regulator essential for hypoxic dormancy.</article-title>
					<source>J Bacteriol</source>
					<volume>184</volume>
					<fpage>6760</fpage>
					<lpage>6767</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0035">
        <label>35</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Voskuil</surname><given-names>MI</given-names></name><name name-style="western"><surname>Schnappinger</surname><given-names>D</given-names></name><name name-style="western"><surname>Visconti</surname><given-names>KC</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>MI</given-names></name><name name-style="western"><surname>Dolganov</surname><given-names>GM</given-names></name><etal/></person-group>
					<year>2003</year>
					<article-title>Inhibition of respiration by nitric oxide induces a <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> dormancy program.</article-title>
					<source>J Exp Med</source>
					<volume>198</volume>
					<fpage>705</fpage>
					<lpage>713</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0036">
        <label>36</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Voskuil</surname><given-names>MI</given-names></name><name name-style="western"><surname>Visconti</surname><given-names>KC</given-names></name><name name-style="western"><surname>Schoolnik</surname><given-names>GK</given-names></name></person-group>
					<year>2004</year>
					<article-title><named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> gene expression during adaptation to stationary phase and low-oxygen dormancy.</article-title>
					<source>Tuberculosis (Edinb)</source>
					<volume>84</volume>
					<fpage>218</fpage>
					<lpage>227</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0037">
        <label>37</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Sherman</surname><given-names>DR</given-names></name><name name-style="western"><surname>Voskuil</surname><given-names>M</given-names></name><name name-style="western"><surname>Schnappinger</surname><given-names>D</given-names></name><name name-style="western"><surname>Liao</surname><given-names>R</given-names></name><name name-style="western"><surname>Harrell</surname><given-names>MI</given-names></name><etal/></person-group>
					<year>2001</year>
					<article-title>Regulation of the <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> hypoxic response gene encoding alpha-crystallin.</article-title>
					<source>Proc Natl Acad Sci U S A</source>
					<volume>98</volume>
					<fpage>7534</fpage>
					<lpage>7539</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0038">
        <label>38</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Barclay</surname><given-names>WR</given-names></name><name name-style="western"><surname>Ebert</surname><given-names>RH</given-names></name><name name-style="western"><surname>Le Roy</surname><given-names>GV</given-names></name><name name-style="western"><surname>Manthei</surname><given-names>RW</given-names></name><name name-style="western"><surname>Roth</surname><given-names>LJ</given-names></name></person-group>
					<year>1953</year>
					<article-title>Distribution and excretion of radioactive isoniazid in tuberculous patients.</article-title>
					<source>J Am Med Assoc</source>
					<volume>151</volume>
					<fpage>1384</fpage>
					<lpage>1388</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0039">
        <label>39</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Allen</surname><given-names>BW</given-names></name><name name-style="western"><surname>Mitchison</surname><given-names>DA</given-names></name></person-group>
					<year>1992</year>
					<article-title>Counts of viable tubercle bacilli in sputum related to smear and culture gradings.</article-title>
					<source>Med Lab Sci</source>
					<volume>49</volume>
					<fpage>94</fpage>
					<lpage>98</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0040">
        <label>40</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">International Union Against Tuberculosis Committee on Prophylaxis</collab>
					<year>1982</year>
					<article-title>Efficacy of various durations of isoniazid preventive therapy for tuberculosis: Five years of follow-up in the IUAT trial.</article-title>
					<source>Bull World Health Organ</source>
					<volume>60</volume>
					<fpage>555</fpage>
					<lpage>564</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0041">
        <label>41</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Walgreen</surname><given-names>A</given-names></name></person-group>
					<year>1948</year>
					<article-title>The time-table of tuberculosis.</article-title>
					<source>Tubercle</source>
					<volume>29</volume>
					<fpage>245</fpage>
					<lpage>251</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0042">
        <label>42</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Munoz-Elias</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Timm</surname><given-names>J</given-names></name><name name-style="western"><surname>Botha</surname><given-names>T</given-names></name><name name-style="western"><surname>Chan</surname><given-names>WT</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>JE</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Replication dynamics of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> in chronically infected mice.</article-title>
					<source>Infect Immun</source>
					<volume>73</volume>
					<fpage>546</fpage>
					<lpage>551</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0043">
        <label>43</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Rees</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Hart</surname><given-names>PD</given-names></name></person-group>
					<year>1961</year>
					<article-title>Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts.</article-title>
					<source>Br J Exp Pathol</source>
					<volume>42</volume>
					<fpage>83</fpage>
					<lpage>88</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0044">
        <label>44</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>McCune</surname><given-names>RM</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Tompsett</surname><given-names>R</given-names></name></person-group>
					<year>1956</year>
					<article-title>Fate of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> in mouse tissues as determined by the microbial enumeration technique. I. The persistence of drug-susceptible tubercle bacilli in the tissues despite prolonged antimicrobial therapy.</article-title>
					<source>J Exp Med</source>
					<volume>104</volume>
					<fpage>737</fpage>
					<lpage>762</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0045">
        <label>45</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Stewart</surname><given-names>PS</given-names></name></person-group>
					<year>2002</year>
					<article-title>Mechanisms of antibiotic resistance in bacterial biofilms.</article-title>
					<source>Int J Med Microbiol</source>
					<volume>292</volume>
					<fpage>107</fpage>
					<lpage>113</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0046">
        <label>46</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Warner</surname><given-names>DF</given-names></name><name name-style="western"><surname>Mizrahi</surname><given-names>V</given-names></name></person-group>
					<year>2006</year>
					<article-title>Tuberculosis chemotherapy: The influence of bacillary stress and damage response pathways on drug efficacy.</article-title>
					<source>Clin Microbiol Rev</source>
					<volume>19</volume>
					<fpage>558</fpage>
					<lpage>570</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0047">
        <label>47</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>McDermott</surname><given-names>W</given-names></name></person-group>
					<year>1958</year>
					<article-title>Microbial persistence.</article-title>
					<source>Yale J Biol Med</source>
					<volume>30</volume>
					<fpage>257</fpage>
					<lpage>291</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0048">
        <label>48</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Eagle</surname><given-names>H</given-names></name></person-group>
					<year>1949</year>
					<article-title>The effect of the size of the inoculum and the age of the infection on the curative dose of penicillin in experimental infections with streptococci, pneumococci, and <named-content content-type="genus-species" xlink:type="simple">Treponema pallidum</named-content>.</article-title>
					<source>J Exp Med</source>
					<volume>90</volume>
					<fpage>595</fpage>
					<lpage>607</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0049">
        <label>49</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Eagle</surname><given-names>H</given-names></name></person-group>
					<year>1952</year>
					<article-title>Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice.</article-title>
					<source>Am J Med</source>
					<volume>13</volume>
					<fpage>389</fpage>
					<lpage>399</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0050">
        <label>50</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Bigger</surname><given-names>J</given-names></name></person-group>
					<year>1944</year>
					<article-title>Treatment of staphylococcal infections with penicillin by intermittent sterilisation.</article-title>
					<source>Lancet</source>
					<volume>247</volume>
					<fpage>497</fpage>
					<lpage>500</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0051">
        <label>51</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Wiuff</surname><given-names>C</given-names></name><name name-style="western"><surname>Zappala</surname><given-names>RM</given-names></name><name name-style="western"><surname>Regoes</surname><given-names>RR</given-names></name><name name-style="western"><surname>Garner</surname><given-names>KN</given-names></name><name name-style="western"><surname>Baquero</surname><given-names>F</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>Phenotypic tolerance: Antibiotic enrichment of noninherited resistance in bacterial populations.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>49</volume>
					<fpage>1483</fpage>
					<lpage>1494</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0052">
        <label>52</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Balaban</surname><given-names>NQ</given-names></name><name name-style="western"><surname>Merrin</surname><given-names>J</given-names></name><name name-style="western"><surname>Chait</surname><given-names>R</given-names></name><name name-style="western"><surname>Kowalik</surname><given-names>L</given-names></name><name name-style="western"><surname>Leibler</surname><given-names>S</given-names></name></person-group>
					<year>2004</year>
					<article-title>Bacterial persistence as a phenotypic switch.</article-title>
					<source>Science</source>
					<volume>305</volume>
					<fpage>1622</fpage>
					<lpage>1625</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0053">
        <label>53</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Barker</surname><given-names>J</given-names></name><name name-style="western"><surname>Scaife</surname><given-names>H</given-names></name><name name-style="western"><surname>Brown</surname><given-names>MR</given-names></name></person-group>
					<year>1995</year>
					<article-title>Intraphagocytic growth induces an antibiotic-resistant phenotype of <named-content content-type="genus-species" xlink:type="simple">Legionella pneumophila</named-content>.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>39</volume>
					<fpage>2684</fpage>
					<lpage>2688</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0054">
        <label>54</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Lewis</surname><given-names>K</given-names></name></person-group>
					<year>2005</year>
					<article-title>Persister cells and the riddle of biofilm survival.</article-title>
					<source>Biochemistry (Mosc)</source>
					<volume>70</volume>
					<fpage>267</fpage>
					<lpage>274</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0055">
        <label>55</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Debbia</surname><given-names>EA</given-names></name><name name-style="western"><surname>Roveta</surname><given-names>S</given-names></name><name name-style="western"><surname>Schito</surname><given-names>AM</given-names></name><name name-style="western"><surname>Gualco</surname><given-names>L</given-names></name><name name-style="western"><surname>Marchese</surname><given-names>A</given-names></name></person-group>
					<year>2001</year>
					<article-title>Antibiotic persistence: The role of spontaneous DNA repair response.</article-title>
					<source>Microb Drug Resist</source>
					<volume>7</volume>
					<fpage>335</fpage>
					<lpage>342</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0056">
        <label>56</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Miller</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>LE</given-names></name><name name-style="western"><surname>Gaggero</surname><given-names>C</given-names></name><name name-style="western"><surname>Mosseri</surname><given-names>R</given-names></name><name name-style="western"><surname>Ingmer</surname><given-names>H</given-names></name><etal/></person-group>
					<year>2004</year>
					<article-title>SOS response induction by beta-lactams and bacterial defense against antibiotic lethality.</article-title>
					<source>Science</source>
					<volume>305</volume>
					<fpage>1629</fpage>
					<lpage>1631</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0057">
        <label>57</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Keren</surname><given-names>I</given-names></name><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Spoering</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaldalu</surname><given-names>N</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>K</given-names></name></person-group>
					<year>2004</year>
					<article-title>Specialized persister cells and the mechanism of multidrug tolerance in <named-content content-type="genus-species" xlink:type="simple">Escherichia coli</named-content>.</article-title>
					<source>J Bacteriol</source>
					<volume>186</volume>
					<fpage>8172</fpage>
					<lpage>8180</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0058">
        <label>58</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Shah</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Khodursky</surname><given-names>A</given-names></name><name name-style="western"><surname>Kaldalu</surname><given-names>N</given-names></name><name name-style="western"><surname>Kurg</surname><given-names>K</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Persisters: A distinct physiological state of <named-content content-type="genus-species" xlink:type="simple">E. coli</named-content>.</article-title>
					<source>BMC Microbiol</source>
					<volume>6</volume>
					<fpage>53</fpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0059">
        <label>59</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Buts</surname><given-names>L</given-names></name><name name-style="western"><surname>Lah</surname><given-names>J</given-names></name><name name-style="western"><surname>Dao-Thi</surname><given-names>MH</given-names></name><name name-style="western"><surname>Wyns</surname><given-names>L</given-names></name><name name-style="western"><surname>Loris</surname><given-names>R</given-names></name></person-group>
					<year>2005</year>
					<article-title>Toxin-antitoxin modules as bacterial metabolic stress managers.</article-title>
					<source>Trends Biochem Sci</source>
					<volume>30</volume>
					<fpage>672</fpage>
					<lpage>679</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0060">
        <label>60</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Gerdes</surname><given-names>K</given-names></name><name name-style="western"><surname>Christensen</surname><given-names>SK</given-names></name><name name-style="western"><surname>Lobner-Olesen</surname><given-names>A</given-names></name></person-group>
					<year>2005</year>
					<article-title>Prokaryotic toxin-antitoxin stress response loci.</article-title>
					<source>Nat Rev Microbiol</source>
					<volume>3</volume>
					<fpage>371</fpage>
					<lpage>382</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0061">
        <label>61</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Arcus</surname><given-names>VL</given-names></name><name name-style="western"><surname>Rainey</surname><given-names>PB</given-names></name><name name-style="western"><surname>Turner</surname><given-names>SJ</given-names></name></person-group>
					<year>2005</year>
					<article-title>The PIN-domain toxin-antitoxin array in mycobacteria.</article-title>
					<source>Trends Microbiol</source>
					<volume>13</volume>
					<fpage>360</fpage>
					<lpage>365</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0062">
        <label>62</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Zhu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Teh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Connell</surname><given-names>N</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Characterization of mRNA interferases from <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>J Biol Chem</source>
					<volume>281</volume>
					<fpage>18638</fpage>
					<lpage>18643</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0063">
        <label>63</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Korch</surname><given-names>SB</given-names></name><name name-style="western"><surname>Henderson</surname><given-names>TA</given-names></name><name name-style="western"><surname>Hill</surname><given-names>TM</given-names></name></person-group>
					<year>2003</year>
					<article-title>Characterization of the <italic>hipA7</italic> allele of <named-content content-type="genus-species" xlink:type="simple">Escherichia coli</named-content> and evidence that high persistence is governed by (p)ppGpp synthesis.</article-title>
					<source>Mol Microbiol</source>
					<volume>50</volume>
					<fpage>1199</fpage>
					<lpage>1213</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0064">
        <label>64</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Dahl</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kraus</surname><given-names>CN</given-names></name><name name-style="western"><surname>Boshoff</surname><given-names>HI</given-names></name><name name-style="western"><surname>Doan</surname><given-names>B</given-names></name><name name-style="western"><surname>Foley</surname><given-names>K</given-names></name><etal/></person-group>
					<year>2003</year>
					<article-title>The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content> in mice.</article-title>
					<source>Proc Natl Acad Sci U S A</source>
					<volume>100</volume>
					<fpage>10026</fpage>
					<lpage>10031</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0065">
        <label>65</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Costerton</surname><given-names>JW</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>PS</given-names></name><name name-style="western"><surname>Greenberg</surname><given-names>EP</given-names></name></person-group>
					<year>1999</year>
					<article-title>Bacterial biofilms: A common cause of persistent infections.</article-title>
					<source>Science</source>
					<volume>284</volume>
					<fpage>1318</fpage>
					<lpage>1322</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0066">
        <label>66</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Spoering</surname><given-names>AL</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>K</given-names></name></person-group>
					<year>2001</year>
					<article-title>Biofilms and planktonic cells of <named-content content-type="genus-species" xlink:type="simple">Pseudomonas aeruginosa</named-content> have similar resistance to killing by antimicrobials.</article-title>
					<source>J Bacteriol</source>
					<volume>183</volume>
					<fpage>6746</fpage>
					<lpage>6751</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0067">
        <label>67</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Darzins</surname><given-names>E</given-names></name><name name-style="western"><surname>Fahr</surname><given-names>G</given-names></name></person-group>
					<year>1956</year>
					<article-title>Cord-forming property, lethality and pathogenicity of Mycobacteria.</article-title>
					<source>Dis Chest</source>
					<volume>30</volume>
					<fpage>642</fpage>
					<lpage>648</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0068">
        <label>68</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Dubos</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>CH</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>WB</given-names></name></person-group>
					<year>1956</year>
					<article-title>Differential characteristics in vitro and in vivo of several substrains of BCG. III. Multiplication and survival in vivo.</article-title>
					<source>Am Rev Tuberc</source>
					<volume>74</volume>
					<fpage>683</fpage>
					<lpage>698</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0069">
        <label>69</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Middlebrook</surname><given-names>G</given-names></name><name name-style="western"><surname>Dobos</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Pierce</surname><given-names>C</given-names></name></person-group>
					<year>1947</year>
					<article-title>Virulence and morphological characteristics of mammalian tubercle bacilli.</article-title>
					<source>J Exp Med</source>
					<volume>86</volume>
					<fpage>175</fpage>
					<lpage>184</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0070">
        <label>70</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Carter</surname><given-names>G</given-names></name><name name-style="western"><surname>Young</surname><given-names>LS</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>LE</given-names></name></person-group>
					<year>2004</year>
					<article-title>A subinhibitory concentration of clarithromycin inhibits <named-content content-type="genus-species" xlink:type="simple">Mycobacterium avium</named-content> biofilm formation.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>48</volume>
					<fpage>4907</fpage>
					<lpage>4910</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0071">
        <label>71</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Teng</surname><given-names>R</given-names></name><name name-style="western"><surname>Dick</surname><given-names>T</given-names></name></person-group>
					<year>2003</year>
					<article-title>Isoniazid resistance of exponentially growing <named-content content-type="genus-species" xlink:type="simple">Mycobacterium smegmatis</named-content> biofilm culture.</article-title>
					<source>FEMS Microbiol Lett</source>
					<volume>227</volume>
					<fpage>171</fpage>
					<lpage>174</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0072">
        <label>72</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Danelishvili</surname><given-names>L</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M</given-names></name><name name-style="western"><surname>Hidaka</surname><given-names>E</given-names></name><name name-style="western"><surname>Katsuyama</surname><given-names>T</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>The ability to form biofilm influences <named-content content-type="genus-species" xlink:type="simple">Mycobacterium avium</named-content> invasion and translocation of bronchial epithelial cells.</article-title>
					<source>Cell Microbiol</source>
					<volume>8</volume>
					<fpage>806</fpage>
					<lpage>814</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0073">
        <label>73</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Roberts</surname><given-names>ME</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>PS</given-names></name></person-group>
					<year>2005</year>
					<article-title>Modelling protection from antimicrobial agents in biofilms through the formation of persister cells.</article-title>
					<source>Microbiology</source>
					<volume>151</volume>
					<fpage>75</fpage>
					<lpage>80</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0074">
        <label>74</label>
        <element-citation publication-type="other" xlink:type="simple">
					<person-group><name name-style="western"><surname>Salomon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lloyd-Smith</surname><given-names>JO</given-names></name><name name-style="western"><surname>Getz</surname><given-names>WM</given-names></name><name name-style="western"><surname>Resch</surname><given-names>S</given-names></name><name name-style="western"><surname>Sanchez</surname><given-names>MS</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Prospects for advancing tuberculosis control efforts through novel therapies.</article-title>
					<comment>PLoS Med 3: e273. doi:10.1371/journal.pmed.0030273</comment>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0075">
        <label>75</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Coates</surname><given-names>AR</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name></person-group>
					<year>2006</year>
					<article-title>New strategies for antibacterial drug design: targeting non-multiplying latent bacteria.</article-title>
					<source>Drugs R D</source>
					<volume>7</volume>
					<fpage>133</fpage>
					<lpage>151</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0076">
        <label>76</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Andries</surname><given-names>K</given-names></name><name name-style="western"><surname>Verhasselt</surname><given-names>P</given-names></name><name name-style="western"><surname>Guillemont</surname><given-names>J</given-names></name><name name-style="western"><surname>Gohlmann</surname><given-names>HW</given-names></name><name name-style="western"><surname>Neefs</surname><given-names>JM</given-names></name><etal/></person-group>
					<year>2005</year>
					<article-title>A diarylquinoline drug active on the ATP synthase of <named-content content-type="genus-species" xlink:type="simple">Mycobacterium tuberculosis</named-content>.</article-title>
					<source>Science</source>
					<volume>307</volume>
					<fpage>223</fpage>
					<lpage>227</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0077">
        <label>77</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Petrella</surname><given-names>S</given-names></name><name name-style="western"><surname>Cambau</surname><given-names>E</given-names></name><name name-style="western"><surname>Chauffour</surname><given-names>A</given-names></name><name name-style="western"><surname>Andries</surname><given-names>K</given-names></name><name name-style="western"><surname>Jarlier</surname><given-names>V</given-names></name><etal/></person-group>
					<year>2006</year>
					<article-title>Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>50</volume>
					<fpage>2853</fpage>
					<lpage>2856</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0078">
        <label>78</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1984</year>
					<article-title>A controlled trial of 2-month, 3-month, and 12-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 60 months.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>130</volume>
					<fpage>23</fpage>
					<lpage>28</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0079">
        <label>79</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1987</year>
					<article-title>Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Hong Kong Chest Service/British Medical Research Council.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>136</volume>
					<fpage>1339</fpage>
					<lpage>1342</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0080">
        <label>80</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1989</year>
					<article-title>A controlled trial of 3-month, 4-month, and 6-month regimens of chemotherapy for sputum-smear-negative pulmonary tuberculosis. Results at 5 years. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>139</volume>
					<fpage>871</fpage>
					<lpage>876</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0081">
        <label>81</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Comstock</surname><given-names>GW</given-names></name><name name-style="western"><surname>Baum</surname><given-names>C</given-names></name><name name-style="western"><surname>Snider</surname><given-names>DE</given-names><suffix>Jr</suffix></name></person-group>
					<year>1979</year>
					<article-title>Isoniazid prophylaxis among Alaskan Eskimos: A final report of the bethel isoniazid studies.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>119</volume>
					<fpage>827</fpage>
					<lpage>830</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0082">
        <label>82</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Norrby</surname><given-names>SR</given-names></name></person-group>
					<year>1990</year>
					<article-title>Short-term treatment of uncomplicated lower urinary tract infections in women.</article-title>
					<source>Rev Infect Dis</source>
					<volume>12</volume>
					<fpage>458</fpage>
					<lpage>467</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0083">
        <label>83</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Wolfson</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hooper</surname><given-names>DC</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>GL</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>MA</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>MN</given-names></name></person-group>
					<year>1990</year>
					<article-title>Mutants of <named-content content-type="genus-species" xlink:type="simple">Escherichia coli</named-content> K-12 exhibiting reduced killing by both quinolone and beta-lactam antimicrobial agents.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>34</volume>
					<fpage>1938</fpage>
					<lpage>1943</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0084">
        <label>84</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>DiNubile</surname><given-names>MJ</given-names></name></person-group>
					<year>1994</year>
					<article-title>Short-course antibiotic therapy for right-sided endocarditis caused by <named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> in injection drug users.</article-title>
					<source>Ann Intern Med</source>
					<volume>121</volume>
					<fpage>873</fpage>
					<lpage>876</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0085">
        <label>85</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Nolan</surname><given-names>CM</given-names></name><name name-style="western"><surname>Beaty</surname><given-names>HN</given-names></name></person-group>
					<year>1976</year>
					<article-title><named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> bacteremia. Current clinical patterns.</article-title>
					<source>Am J Med</source>
					<volume>60</volume>
					<fpage>495</fpage>
					<lpage>500</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0086">
        <label>86</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Ribera</surname><given-names>E</given-names></name><name name-style="western"><surname>Gomez-Jimenez</surname><given-names>J</given-names></name><name name-style="western"><surname>Cortes</surname><given-names>E</given-names></name><name name-style="western"><surname>del Valle</surname><given-names>O</given-names></name><name name-style="western"><surname>Planes</surname><given-names>A</given-names></name><etal/></person-group>
					<year>1996</year>
					<article-title>Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided <named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> endocarditis. A randomized, controlled trial.</article-title>
					<source>Ann Intern Med</source>
					<volume>125</volume>
					<fpage>969</fpage>
					<lpage>974</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0087">
        <label>87</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Small</surname><given-names>PM</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>HF</given-names></name></person-group>
					<year>1990</year>
					<article-title>Vancomycin for <named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> endocarditis in intravenous drug users.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>34</volume>
					<fpage>1227</fpage>
					<lpage>1231</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0088">
        <label>88</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Kaatz</surname><given-names>GW</given-names></name><name name-style="western"><surname>Seo</surname><given-names>SM</given-names></name></person-group>
					<year>1996</year>
					<article-title>In vitro activities of oxazolidinone compounds U100592 and U100766 against <named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> and <named-content content-type="genus-species" xlink:type="simple">Staphylococcus epidermidis</named-content>.</article-title>
					<source>Antimicrob Agents Chemother</source>
					<volume>40</volume>
					<fpage>799</fpage>
					<lpage>801</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0089">
        <label>89</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Karchmer</surname><given-names>AW</given-names></name></person-group>
					<year>1985</year>
					<article-title>Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy.</article-title>
					<source>Am J Med</source>
					<volume>78</volume>
					<fpage>116</fpage>
					<lpage>127</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0090">
        <label>90</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Korzeniowski</surname><given-names>O</given-names></name><name name-style="western"><surname>Sande</surname><given-names>MA</given-names></name></person-group>
					<year>1982</year>
					<article-title>Combination antimicrobial therapy for <named-content content-type="genus-species" xlink:type="simple">Staphylococcus aureus</named-content> endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study.</article-title>
					<source>Ann Intern Med</source>
					<volume>97</volume>
					<fpage>496</fpage>
					<lpage>503</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0091">
        <label>91</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1986</year>
					<article-title>Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>133</volume>
					<fpage>779</fpage>
					<lpage>783</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0092">
        <label>92</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1988</year>
					<article-title>Five-year follow-up of a clinical trial of three 6-month regimens of chemotherapy given intermittently in the continuation phase in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>137</volume>
					<fpage>1147</fpage>
					<lpage>1150</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0093">
        <label>93</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Dutt</surname><given-names>AK</given-names></name><name name-style="western"><surname>Moers</surname><given-names>D</given-names></name><name name-style="western"><surname>Stead</surname><given-names>WW</given-names></name></person-group>
					<year>1989</year>
					<article-title>Smear- and culture-negative pulmonary tuberculosis: Four-month short-course chemotherapy.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>139</volume>
					<fpage>867</fpage>
					<lpage>870</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0094">
        <label>94</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<collab xlink:type="simple">[No authors listed]</collab>
					<year>1991</year>
					<article-title>Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Hong Kong Chest Service/ British Medical Research Council.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>143</volume>
					<fpage>700</fpage>
					<lpage>706</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0095">
        <label>95</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Snider</surname><given-names>DE</given-names></name><name name-style="western"><surname>Graczyk</surname><given-names>J</given-names></name><name name-style="western"><surname>Bek</surname><given-names>E</given-names></name><name name-style="western"><surname>Rogowski</surname><given-names>J</given-names></name></person-group>
					<year>1984</year>
					<article-title>Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampin, and pyrazinamide with and without streptomycin.</article-title>
					<source>Am Rev Respir Dis</source>
					<volume>130</volume>
					<fpage>1091</fpage>
					<lpage>1094</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0096">
        <label>96</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Benator</surname><given-names>D</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></name><name name-style="western"><surname>Bozeman</surname><given-names>L</given-names></name><name name-style="western"><surname>Burman</surname><given-names>W</given-names></name><name name-style="western"><surname>Cantazaro</surname><given-names>A</given-names></name><etal/></person-group>
					<year>2002</year>
					<article-title>Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: A randomised clinical trial.</article-title>
					<source>Lancet</source>
					<volume>360</volume>
					<fpage>528</fpage>
					<lpage>534</lpage>
				</element-citation>
      </ref>
      <ref id="pmed-0040120-b0097">
        <label>97</label>
        <element-citation publication-type="journal" xlink:type="simple">
					<person-group><name name-style="western"><surname>Perriens</surname><given-names>JH</given-names></name><name name-style="western"><surname>St Louis</surname><given-names>ME</given-names></name><name name-style="western"><surname>Mukadi</surname><given-names>YB</given-names></name><name name-style="western"><surname>Brown</surname><given-names>C</given-names></name><name name-style="western"><surname>Prignot</surname><given-names>J</given-names></name><etal/></person-group>
					<year>1995</year>
					<article-title>Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.</article-title>
					<source>N Engl J Med</source>
					<volume>332</volume>
					<fpage>779</fpage>
					<lpage>784</lpage>
				</element-citation>
      </ref>
    </ref-list>
  </back>
</article>